Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
Public ClinicalTrials.gov record NCT02842086. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to assess the rates of HIV-1 infection in Men (MSM) and transgender women (TGW) who have sex with men and who are administered daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) with a minimum follow-up of 48 weeks and at least 50% of participants have 96 weeks of follow-up after randomization.
Study identification
- NCT ID
- NCT02842086
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 5,399 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 1, 2016
- Primary completion
- Jan 30, 2019
- Completion
- Jul 28, 2026
- Last update posted
- Sep 7, 2026
2016 – 2026
United States locations
- U.S. sites
- 54
- U.S. states
- 21
- U.S. cities
- 41
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Beverly Hills | California | 90211 | — |
| Not listed | Los Angeles | California | 90036 | — |
| Not listed | Los Angeles | California | 90069 | — |
| Not listed | Newport Beach | California | 92663 | — |
| Not listed | Oakland | California | 94609 | — |
| Not listed | Sacramento | California | 95817 | — |
| Not listed | Sacramento | California | 95825 | — |
| Not listed | San Diego | California | 92103 | — |
| Not listed | San Francisco | California | 94102 | — |
| Not listed | San Francisco | California | 94103 | — |
| Not listed | San Francisco | California | 94118 | — |
| Not listed | Torrance | California | 90502 | — |
| Not listed | Aurora | Colorado | 80045 | — |
| Not listed | Denver | Colorado | 80209 | — |
| Not listed | New Haven | Connecticut | 06510 | — |
| Not listed | Washington D.C. | District of Columbia | 20009 | — |
| Not listed | Washington D.C. | District of Columbia | 20036 | — |
| Not listed | Fort Lauderdale | Florida | 33308 | — |
| Not listed | Fort Lauderdale | Florida | 33316 | — |
| Not listed | Ft. Pierce | Florida | 34982 | — |
| Not listed | Miami | Florida | 33136 | — |
| Not listed | Orlando | Florida | 32803 | — |
| Not listed | Pensacola | Florida | 32504 | — |
| Not listed | West Palm Beach | Florida | 33407 | — |
| Not listed | Atlanta | Georgia | 30308 | — |
| Not listed | Atlanta | Georgia | 30309 | — |
| Not listed | Atlanta | Georgia | 30312 | — |
| Not listed | Macon | Georgia | 31201 | — |
| Not listed | Chicago | Illinois | 60612 | — |
| Not listed | Chicago | Illinois | 60613 | — |
| Not listed | New Orleans | Louisiana | 70119 | — |
| Not listed | Boston | Massachusetts | 02215 | — |
| Not listed | Springfield | Massachusetts | 01105 | — |
| Not listed | Berkley | Michigan | 48072 | — |
| Not listed | Detroit | Michigan | 48202 | — |
| Not listed | Minneapolis | Minnesota | 55415 | — |
| Not listed | Las Vegas | Nevada | 89104 | — |
| Not listed | Somers Point | New Jersey | 08244 | — |
| Not listed | Santa Fe | New Mexico | 87505 | — |
| Not listed | New York | New York | 10029 | — |
| Not listed | New York | New York | 10032 | — |
| Not listed | New York | New York | 10037 | — |
| Not listed | The Bronx | New York | 10467 | — |
| Not listed | Chapel Hill | North Carolina | 27599-7215 | — |
| Not listed | Huntersville | North Carolina | 28078 | — |
| Not listed | Cleveland | Ohio | 44109 | — |
| Not listed | Philadelphia | Pennsylvania | 19107 | — |
| Not listed | Austin | Texas | 78705 | — |
| Not listed | Dallas | Texas | 75208 | — |
| Not listed | Dallas | Texas | 75246 | — |
| Not listed | Houston | Texas | 77098 | — |
| Not listed | Seattle | Washington | 98101 | — |
| Not listed | Seattle | Washington | 98104 | — |
| Not listed | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02842086, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 7, 2026 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02842086 live on ClinicalTrials.gov.